JPietersen
Sep 29, 6:01 PM
$ELDN This company is dead money for the next 18 months, at least. This was from the latest ER and as reported at the Transplant Society mtg in Sydney:
The global trial is on track to initiate in late 2026 and enroll approximately 600 patients, with a primary endpoint of non-inferiority versus tacrolimus at 52 weeks based on a composite of biopsy-proven acute rejection (BPAR), graft loss and death.
My comments: 600 patients! Starting in late 2026. Let's assume it takes them 3-6 months to find 600 patients, and this may be optimistic, all of whom need to be followed for 52 weeks, then data analysis and readout. All this when they only have enough money to last until the 2nd qtr of 2027. With a market cap north of 200 million without even a P3 already begun. As some other poster said, this will dwindle below 2 and they will do a raise then, instead of when it was at 4 (Thanks, DA!)
1 replies
